Phase 3, Multicenter Open‐Label study to investigate the efficacy of elbasvir and grazoprevir fixed‐dose combination for 8 weeks in treatment‐naïve, HCV GT1b‐infected patients, with non‐severe fibrosis - Université d'Angers Accéder directement au contenu
Article Dans Une Revue Liver International Année : 2020

Phase 3, Multicenter Open‐Label study to investigate the efficacy of elbasvir and grazoprevir fixed‐dose combination for 8 weeks in treatment‐naïve, HCV GT1b‐infected patients, with non‐severe fibrosis

Fichier non déposé

Dates et versions

hal-03287285 , version 1 (15-07-2021)

Identifiants

Citer

Armand Abergel, Tarik Asselah, Arianne Mallat, Brigitte Chanteranne, Frederic Faure, et al.. Phase 3, Multicenter Open‐Label study to investigate the efficacy of elbasvir and grazoprevir fixed‐dose combination for 8 weeks in treatment‐naïve, HCV GT1b‐infected patients, with non‐severe fibrosis. Liver International, 2020, 40 (8), pp.1853-1859. ⟨10.1111/liv.14502⟩. ⟨hal-03287285⟩
23 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More